Bing

SEARCH HISTORY

CEO and President Pedro Lichtinger bought 11,000 shares of OPTR stock on Nov. 8, 2012 at the average price of $9.08. Former CEO Pedro Lichtinger sold 148,000 shares of OPTR stock on April 8, 2013 at the average price of $14.69. ReachLocal, Inc.
Guru Focus · 4/14/2013
CEO and President Pedro Lichtinger bought 11,000 shares of OPTR stock on Nov. 8, 2012 at the average price of $9.08. Former CEO Pedro Lichtinger sold 148,000 shares of OPTR stock on April 8, 2013 at the average price of $14.69. ReachLocal, Inc.
NASDAQ · 4/14/2013
The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 124.2% …
The Street · 5/17/2012
More from Bing News
Optimer Pharmaceuticals' (OPTR) stock is jumping this morning after the company won US approval to sell its new drug, Dificid, for hospital infections. The drug was approved to treat diarrhea related to the intestinal infection Clostridium difficile.
Minyanville · ByBrett Chase · 5/31/2011
The prescription trends also suggest that OPTR is unlikely to deliver compelling sales growth for Dificid in the near term, and could disappoint on quarterly sales expectations, which will keep pressure on the stock. Most importantly, Dificid could be what ...
Seeking Alpha · 2/21/2013
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced the initial public offering of 7,000,000 shares of its common stock at a price of $7.00 per share, below the expected $8-$9 range which was also lowerd. The stock will open today on the NASDAQ …
StreetInsider · 2/9/2007
That's great news for Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR), Cyclacel Pharmaceuticals ... have been easy to throw in the towel on this stock. It would have been a mistake, however. Shares of CYTR have been on the mend all year long, and have …
Smallcap Network · ByJames E. Brumley · 5/29/2012
SAN DIEGO, Aug 05, 2013 (GLOBE NEWSWIRE via COMTEX) -- The Shareholders Foundation, Inc. announces that an investor who currently holds Optimer Pharmaceuticals, Inc. (OPTR) shares filed ... Inc common stock for $10.75 per share in cash, or …
Market Watch · 8/5/2013
With these “truths” under our belt, let’s take a glance at the latest action encompassing Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR). In preparation for this quarter, a total of 11 of the hedge funds we track held long positions in this stock ...
INSIDER MONKEY · 6/12/2013
Optimer Pharmaceutical (NASDAQ: OPTR) is a biopharmaceutical company that focuses on anti-infective products, including ones that treat gastrointestinal infections and related diseases. The stock dipped last month, and looks to have found support just ...
Investor Place · 7/12/2011